A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Fibroblast growth factor 1 (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors CardioVascular BioTherapeutics Inc
- 30 Apr 2019 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 30 Apr 2019 Planned primary completion date changed from 15 Dec 2020 to 15 Dec 2021.
- 30 Apr 2019 Planned initiation date changed from 1 Dec 2019 to 1 Dec 2020.